GLP-1 Weight-Loss Drugs May Elevate Bone and Tendon Injury Risk, Study Finds
TL;DR Summary
A large study suggests GLP-1 receptor agonists like Ozempic may increase the risk of bone and tendon injuries, with osteoporosis and gout cited as examples, highlighting potential long-term safety trade-offs for these weight-loss/diabetes medications.
- GLP-1 drugs like Ozempic can raise bone and tendon injury risk, study suggests The Washington Post
- GLP-1s may increase risk of osteoporosis and gout, new research finds NBC News
- GLP-1 drugs linked to higher fracture risk, osteoporosis and gout, new studies suggest Fox News
- Bone health: GLP-1s may increase osteoporosis risk Medical News Today
- Tendon Rupture Risk Linked With GLP-1 Use in Patients With Obesity Medscape
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
18 min
vs 18 min read
Condensed
99%
3,581 → 34 words
Want the full story? Read the original article
Read on The Washington Post